Literature DB >> 19838164

Grading of gastric foveolar-type dysplasia in Barrett's esophagus.

Dipti Mahajan1, Ana E Bennett, Xiaobo Liu, James Bena, Mary P Bronner.   

Abstract

Dysplasia is the gold standard biomarker of cancer risk in Barrett's esophagus, but its diagnosis remains difficult. This is due in part to its multitude of histological appearances. One aspect receiving little attention concerns gastric-type Barrett's dysplasia, which is distinctly different from the well-established intestinal variant. Recognition of gastric-type dysplasia and development of separate grading criteria are required. The prevalence, diagnostic criteria, and natural history of gastric-type Barrett's dysplasia were systematically evaluated in 1854 endoscopic biopsies from a cohort of 200 consecutive Barrett's dysplasia patients. Goblet cells were present in all cases, confirming the utility of this defining feature of Barrett's esophagus. The prevalence of Barrett's gastric-type dysplasia was 15% at the patient level (30 of 200 patients) and 20% at the biopsy level (166 of 852 dysplastic biopsies). Gastric-type dysplasia uniformly showed non-stratified, basally oriented nuclei as the major criterion for distinguishing it from intestinal-type Barrett's dysplasia. As such, loss of nuclear polarity, as the most objective criterion to distinguish intestinal-type low- and high-grade dysplasia, cannot be applied to gastric-type dysplasia. Rather, discriminatory features included increased nuclear size with a high-grade dysplasia cutoff by receiver operating characteristic (ROC) analysis approximating 3-4 times the size of a mature lymphocyte, providing an optimal sensitivity, specificity, and area under the curve of 0.78, 0.90, and 0.90 (95% CI: (0.87, 0.93)), respectively. Crowded, irregular glandular architecture (P<0.001) was more common in high-grade lesions (P<0.001), as was eosinophilic and oncocytic cytoplasm relative to the mucinous cytoplasm (P<0.001), prominent nucleoli (P<0.001), mild nuclear pleomorphism (P<0.001), and villiform architecture (P<0.001). During follow-up, 64% (7 of 11) of patients with pure gastric and 26% (5 of 19) with mixed gastric and intestinal dysplasia underwent neoplastic progression. The recognition of Barrett's gastric-type dysplasia and use of the proposed grading criteria should promote better diagnostic classification of the Barrett's neoplastic spectrum.

Entities:  

Mesh:

Year:  2009        PMID: 19838164     DOI: 10.1038/modpathol.2009.147

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  16 in total

Review 1.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

Review 2.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

Review 3.  Barrett oesophagus: lessons on its origins from the lesion itself.

Authors:  Stuart A C McDonald; Danielle Lavery; Nicholas A Wright; Marnix Jansen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-11-04       Impact factor: 46.802

4.  Overdiagnosis of high-grade dysplasia in Barrett's esophagus: a multicenter, international study.

Authors:  Nikhil A Sangle; Shari L Taylor; Mary J Emond; Michelle Depot; Bergein F Overholt; Mary P Bronner
Journal:  Mod Pathol       Date:  2015-02-13       Impact factor: 7.842

Review 5.  [Intraepithelial neoplasia of Barrett's esophagus: prognosis of potential malignancy].

Authors:  M Werner; S Lassmann
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

6.  The transcription factor MIST1 is a novel human gastric chief cell marker whose expression is lost in metaplasia, dysplasia, and carcinoma.

Authors:  Jochen K M Lennerz; Seok-Hyung Kim; Edward L Oates; Won Jae Huh; Jason M Doherty; Xiaolin Tian; Andrew J Bredemeyer; James R Goldenring; Gregory Y Lauwers; Young-Kee Shin; Jason C Mills
Journal:  Am J Pathol       Date:  2010-08-13       Impact factor: 4.307

7.  Loss of cell polarity protein Lgl2 in foveolar-type gastric dysplasia: correlation with expression of the apical marker aPKC-zeta.

Authors:  Mikhail Lisovsky; Fumihiro Ogawa; Karen Dresser; Bruce Woda; Gregory Y Lauwers
Journal:  Virchows Arch       Date:  2010-10-13       Impact factor: 4.064

8.  Dysplasia discrimination in intestinal-type neoplasia of the esophagus and colon via digital image analysis.

Authors:  David R Martin; David R Braxton; Alton B Farris
Journal:  Virchows Arch       Date:  2016-08-05       Impact factor: 4.064

Review 9.  [Subjective grading of Barrett's neoplasia by pathologists: correlation with objective histomorphometric variables].

Authors:  E Sabo; G Klorin; E Montgomery; K C Drumea; O Ben-Izhak; J Lachter; M Vieth
Journal:  Pathologe       Date:  2013-03       Impact factor: 1.011

Review 10.  BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia.

Authors:  Cathy Bennett; Paul Moayyedi; Douglas A Corley; John DeCaestecker; Yngve Falck-Ytter; Gary Falk; Nimish Vakil; Scott Sanders; Michael Vieth; John Inadomi; David Aldulaimi; Khek-Yu Ho; Robert Odze; Stephen J Meltzer; Eamonn Quigley; Stuart Gittens; Peter Watson; Giovanni Zaninotto; Prasad G Iyer; Leo Alexandre; Yeng Ang; James Callaghan; Rebecca Harrison; Rajvinder Singh; Pradeep Bhandari; Raf Bisschops; Bita Geramizadeh; Philip Kaye; Sheila Krishnadath; M Brian Fennerty; Hendrik Manner; Katie S Nason; Oliver Pech; Vani Konda; Krish Ragunath; Imdadur Rahman; Yvonne Romero; Richard Sampliner; Peter D Siersema; Jan Tack; Tony C K Tham; Nigel Trudgill; David S Weinberg; Jean Wang; Kenneth Wang; Jennie Y Y Wong; Stephen Attwood; Peter Malfertheiner; David MacDonald; Hugh Barr; Mark K Ferguson; Janusz Jankowski
Journal:  Am J Gastroenterol       Date:  2015-04-14       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.